ZNT8 is a zinc transporter related to insulin secretion in humans. In particular, ZNT8 is critical for the accumulation of zinc into beta cell secretory granules and the maintenance of stored insulin as tightly packaged hexamers.

Seropositivity for ZnT8 autoantibody (≥15 IU/mL) is supportive of:-A diagnosis of type 1 diabetes-A high risk for future development of diabetes-A current or future need for insulin therapy in patients with diabetes

Oct 6, 2009 · Zinc transporter 8 (ZnT8) is an islet β-cell secretory granule membrane protein recently identified as an autoantibody antigen in type 1 diabetes. The aim of this study was to determine the prevalence and role of antibodies to ZnT8 (ZnT8As) in adult-onset diabetes.

Zinc transporter 8 (ZnT8), a protein highly specific to pancreatic insulin-producing beta cells, is vital for the biosynthesis and secretion of insulin. ZnT8 autoantibodies (ZnT8A) are among the most recently discovered and least-characterised islet autoantibodies.

Detects zinc transporter 8 autoantibodies (ZnT8), an autoimmune diabetes marker that is instrumental in the diagnosis of new-onset type 1 diabetes. What does it mean if your result is Positive? One or more of these autoantibodies are detected in 93% to 96% of patients with type 1 diabetes, both adults and children.

Zinc transporter 8 (ZnT8), an islet-specific gene product localized to the β-cell insulin granule, is recently identified as an autoantigen in T1D . The introduction of zinc transporter 8 autoantibody (ZnT8A) in the routine diagnostic process of T1D may improve the overall autoantibody sensitivity .

Type 1 diabetes is characterized by the presence of autoantibodies against particular pancreatic proteins, such as ZnT8 (zinc transporter 8). The ZnT8 autoantibodies test is used to determine whether or not these autoantibodies are present in the blood of the patient being evaluated.

Feb 22, 2024 · Our recent studies have detected ZnT8 autoantibodies targeting extracellular epitopes in patients with new-onset T1D (5–7), indicating that ZnT8 is a unique cell-surface marker for β-cell recognition by antigen-specific autoreactive B cells.

ZnT8 is specifically expressed in the pancreatic β-cells and has been identified as a novel target autoantigen in patients with type 1 diabetes. Autoantibodies to ZnT8 (ZnT8A) are detected in 50-60% of Japanese patients with acute-onset and 20% with slow-onset type 1 diabetes.

ZnT8 antibody distinguishes type 1 and type 2 diabetes mellitus. ZnT8 antibody identifies relatives of diabetic patients at most risk for developing diabetes. ZnT8 antibody predicts the future need for insulin treatment in adult-onset diabetic patients.